title: Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
abstract: Based on the results of large clinical trials, several low-molecular-weight heparins (LMWHs) have been approved for prophylaxis and the treatment of venous and arterial thromboembolism. As a result of expiration or pending expiration of patent protection of the originator LMWHs, the first generic LMWH enoxaparin has been approved by the Food and Drug Administration for clinical use in all medical indications. The European Medicines Agency has set up guidelines for the production of generic LMWHs. The International Society of Thrombosis, the North American Thrombosis Forum and other scientific organizations raised concerns regarding the safety of generic LMWHs due to economic reasons. These organizations have published statements for the production of generic LMWHs to ensure the quality of the products and the safety for patients. Ideally, the differences between the actual recommendations and guidelines for the production of generic version of LMWHs should be harmonized.
authors.affiliation: Clinical Pharmacology, Faculty of Medicine Mannheim, Mannheim, Germany. job.harenberg@medma.uni-heidelberg.de
authors.forename: Job
authors.initials: J
authors.lastname: Harenberg
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000592:standards*; D016568:Drugs, Generic / Q000008:administration & dosage / Q000592:standards*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000592:standards*; D006801:Humans; D004364:Pharmaceutical Preparations; D017410:Practice Guidelines as Topic; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000925:Anticoagulants; D016568:Drugs, Generic; D006495:Heparin, Low-Molecular-Weight; D004364:Pharmaceutical Preparations